Common Shares Outstanding: The number of class A shares currently held by investors.
Provectus Biopharmaceuticals, Inc. (PVCT) had Common Shares Outstanding of 420.28M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-1.29M |
|
-- |
|
-- |
|
$1.25M |
|
$-1.25M |
|
$-0.05M |
|
$-1.30M |
|
$-1.30M |
|
$-1.30M |
|
$-1.30M |
|
$-1.30M |
|
$-1.30M |
|
$-1.25M |
|
$-1.25M |
|
420.28M |
|
420.28M |
|
$0.00 |
|
$0.00 |
|
| Balance Sheet Financials | |
$0.46M |
|
$0.00M |
|
$0.12M |
|
$0.58M |
|
$7.24M |
|
-- |
|
$0.07M |
|
$7.31M |
|
$-6.75M |
|
$-6.73M |
|
$-6.73M |
|
|
Common Shares Outstanding |
420.28M |
| Cash Flow Statement Financials | |
$-0.36M |
|
-- |
|
$0.33M |
|
$0.25M |
|
$0.22M |
|
$-0.03M |
|
$0.31M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.06 |
|
-- |
|
-- |
|
-- |
|
-0.39 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-0.36M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
19.28% |
|
19.33% |
|
-225.24% |
|
19.33% |
|
$-0.02 |
|
$-0.00 |
|
$-0.00 |
|